ArticleTherapeutics and clinical risk management2007
History and evolution of antibiotic resistance in coagulase-negative staphylococci: Susceptibility profiles of new anti-staphylococcal agents.
Article in Therapeutics and clinical risk management, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 70 citations in OpenAlex.
- Emerging threats and zoonotic implications of antibiotic-resistant Staphylococcus spp. in domesticated cats: a review.Antonie van Leeuwenhoek · 2026Review
- Genome Sequence of Environmental Isolate Staphylococcus aureus OS-6, Isolated from a Soil Sample.Microbiology resource announcements · 2023Article
- Evolution of the Prevalence of Antibiotic Resistance toVeterinary sciences · 2023Article
- Combinatorial efficacy of Manuka honey and antibiotics in theFrontiers in cellular and infection microbiology · 2023Article
- How Combined Macrolide Nanomaterials are Effective Against Resistant Pathogens? A Comprehensive Review of the Literature.International journal of nanomedicine · 2023Review
- Identification and Characterization of a Vancomycin Intermediate-ResistantInfection and drug resistance · 2023Article
- Clinical Infections, Antibiotic Resistance, and Pathogenesis ofMicroorganisms · 2022Review
- Reservoir of Antibiotic Residues and Resistant Coagulase Negative Staphylococci in a Healthy Population in the Greater Accra Region, Ghana.Antibiotics (Basel, Switzerland) · 2022Article
- Prevalence and antibiogram of coagulase negative Staphylococci in bioaerosols from different indoors of a university in India.BMC microbiology · 2020Article
- Investigation of SCCmec types I-IV in clinical isolates of methicillin-resistant coagulase-negative staphylococci in Ahvaz, Southwest Iran.Bioscience reports · 2020Article
- Whole genome sequencing revealed new molecular characteristics in multidrug resistant staphylococci recovered from high frequency touched surfaces in London.Scientific reports · 2019Article
- Inoculation Pneumonia Caused by Coagulase NegativeFrontiers in microbiology · 2019Article
- Improved multiplex PCR primers for rapid identification of coagulase-negative staphylococci.Archives of microbiology · 2018Article
- Artificial opsonin enhances bacterial phagocytosis, oxidative burst and chemokine production by human neutrophils.Pathogens and disease · 2017Article
- Article
- Article
- Prevalence and antibiotic resistance of coagulase-negativeInfection and drug resistance · 2017Article
- Antibiotic resistance and mecA characterization of coagulase-negative staphylococci isolated from three hotels in London, UK.Frontiers in microbiology · 2015Article
- Epidemiology and prognosis of coagulase-negative staphylococcal endocarditis: impact of vancomycin minimum inhibitory concentration.PloS one · 2015Article
- Methicillin-resistant coagulase-negative staphylococci from healthy dogs in Nsukka, Nigeria.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coagulase-negative staphylococci (CNS) are a heterogenous group of Gram-positive cocci that are widespread commensals among mammalia. Unlike their coagulase-positive counterpart, Staphylococcus aureus, CNS produce few virulence patterns and normally refrain from invading tissue. Yet, not only can CNS cause infections in normal host tissue, but modern medicine has also seen their rise as opportunists that display adherence to medical device materials to produce a protective biofilm. CNS have historically been more resistant to antimicrobials, including the beta-lactam antibiotics, than S. aureus and some hospitals reveal rates of oxacillin resistance in CNS approaching 90%. Cross resistance to non-beta-lactam agents has been a recurrent theme over the past 40 years in the CNS. Thus, there has been a pressing need for newer antimicrobial agents with good antistaphylococcal activity. Those new agents tend to have excellent antistaphylococcal activity include daptomycin, linezolid, oritavancin, telavancin, tigecycline, dalbavancin, new quinolones, and ceftibiprole, several of which have unique mechanisms of action. The MIC₉₀ for these new compounds typically ranges from 0.5-4 mug/mL. Staphylococcal biofilm formation is quite common in CNS infections and markedly increases the MIC for most older antimicrobials. Several of the newer agents offer some promise of penetration of biofilm to inhibit or kill adherent staphylococci. CNS will likely remain a major cause of infections in the modern age, evolve further antimicrobial resistance mechanisms, and require development of newer antimicrobials for curative therapy.
Indexed as
Identifiers
18516271PMC2387300W34831798What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.